A novel monoclonal antibody when added to statin therapy substantially cuts LDL cholesterol levels beyond reductions achieved with statin therapy alone, a phase II study found…Subcutaneous injection every two weeks dropped LDL by 40% to 72% more than placebo across the doses tested among patients uncontrolled on their background regimen of atorvastatin (Lipitor), James M. McKenney, PharmD, of National Clinical Research in Richmond, Va., reported…"This is a wow," said conference co-chair Rick A. Nishimura, MD, of the Mayo Clinic in Rochester, Minn., calling the monoclonal antibody a potential game changer at the press conference.

MedPage Today by Robert Jasmer   3/26/12

Tags: James M. McKenney, lipids, Mayo Clinic Rochester, National Clinical Research, Preventive Medicine, Rick A. Nishimura